http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020216806-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bfc706d2687ef275c2654c140de31e4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 |
| filingDate | 2018-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a16c37f50b04f99c77ff1e4a468774af |
| publicationDate | 2020-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020216806-A1 |
| titleOfInvention | Allogeneic Dendritic Cells For Use In Cancer Treatment |
| abstract | Disclosed is a pro-inflammatory dendritic cell with improved ability to activate allo-geneic T-cells through the direct pathway of allorecognition. The dendritic cell is infected with an adenovirus. Further, the pro-inflammatory dendritic cell has been obtained by: —providing an immature dendritic cell; —infecting the dendritic cell with an adenovirus; and —maturating the immature dendritic cell into a pro-inflammatory dendritic cell by addition of the Toll-like receptor 3 (TLR3)-ligand poly-I:C, a TLR7/8-ligand, such as Resiquimod, and interferon gamma (IFN-γ) to induce maturation of the immature dendritic cell. |
| priorityDate | 2017-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 344.